{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:10:33Z","timestamp":1771596633761,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,20]]},"DOI":"10.7759\/cureus.103966","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T13:22:07Z","timestamp":1771593727000},"source":"Crossref","is-referenced-by-count":0,"title":["Integrating Circulating Tumor DNA (ctDNA) Into Postoperative Surveillance After the Resection of Intrahepatic Cholangiocarcinoma: A Proposed Hybrid Imaging-Molecular Framework"],"prefix":"10.7759","author":[{"given":"Mihira","family":"Mundhava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Jangid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khushbu","family":"Jangir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niteesh Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavin","family":"Vadodariya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-14975-w","article-title":"Is repeat resection for recurrent intrahepatic cholangiocarcinoma warranted? Outcomes of an international analysis","volume":"31","author":"Holzner ML","year":"2024","unstructured":"Holzner ML, Mazzaferro V, Busset MD, et al.. Is repeat resection for recurrent intrahepatic cholangiocarcinoma warranted? Outcomes of an international analysis. Ann Surg Oncol. 2024, 31:4397-404. 10.1245\/s10434-024-14975-w","journal-title":"Ann Surg Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.58931\/cht.2024.3360","article-title":"Minimal residual disease in myeloma in 2024: where we are today","volume":"3","author":"De la Torre AH","year":"2024","unstructured":"De la Torre AH, Ram\u00edrez Ibarguen AF. Minimal residual disease in myeloma in 2024: where we are today. Can Hematol Today. 2024, 3:47-54. 10.58931\/cht.2024.3360","journal-title":"Can Hematol Today"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223722","article-title":"Measurable residual disease in hematological cancers","volume":"16","author":"Jamroziak K","year":"2024","unstructured":"Jamroziak K, Pu\u0142a B. Measurable residual disease in hematological cancers. Cancers (Basel). 2024, 16:3722. 10.3390\/cancers16223722","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease - latest advances and implications for cure","volume":"16","author":"Pantel K","year":"2019","unstructured":"Pantel K, Alix-Panabi\u00e8res C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019, 16:409-24. 10.1038\/s41571-019-0187-3","journal-title":"Nat Rev Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-023-1018-6","article-title":"Minimal residual disease in solid tumors: an overview","volume":"17","author":"Ma Y","year":"2023","unstructured":"Ma Y, Gan J, Bai Y, Cao D, Jiao Y. Minimal residual disease in solid tumors: an overview. Front Med. 2023, 17:649-74. 10.1007\/s11684-023-1018-6","journal-title":"Front Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215364","article-title":"Liquid biopsy to detect minimal residual disease: methodology and impact","volume":"13","author":"Honor\u00e9 N","year":"2021","unstructured":"Honor\u00e9 N, Galot R, van Marcke C, Limaye N, Machiels JP. Liquid biopsy to detect minimal residual disease: methodology and impact. Cancers (Basel). 2021, 13:5364. 10.3390\/cancers13215364","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2014.13907","article-title":"Minimal residual disease monitoring: the new standard for treatment evaluation of haematological malignancies?","volume":"144","author":"Hauwel M","year":"2014","unstructured":"Hauwel M, Matthes T. Minimal residual disease monitoring: the new standard for treatment evaluation of haematological malignancies?. Swiss Med Wkly. 2014, 144:w13907. 10.4414\/smw.2014.13907","journal-title":"Swiss Med Wkly"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1616064","article-title":"Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives","volume":"13","author":"Wang Y","year":"2025","unstructured":"Wang Y, Li Y, Liang Z, et al.. Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives. Front Cell Dev Biol. 2025, 13:1616064. 10.3389\/fcell.2025.1616064","journal-title":"Front Cell Dev Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000507923","article-title":"Current opinion about hepatocellular carcinoma <10 mm","volume":"102","author":"Dong Y","year":"2021","unstructured":"Dong Y, Teufel A, Wang WP, Dietrich CF. Current opinion about hepatocellular carcinoma &lt;10 mm. Digestion. 2021, 102:335-41. 10.1159\/000507923","journal-title":"Digestion"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050893","article-title":"Integrating CT radiomics and clinical features to optimize TACE technique decision-making in hepatocellular carcinoma","volume":"17","author":"Masthoff M","year":"2025","unstructured":"Masthoff M, Irle M, Kaldewey D, et al.. Integrating CT radiomics and clinical features to optimize TACE technique decision-making in hepatocellular carcinoma. Cancers (Basel). 2025, 17:893. 10.3390\/cancers17050893","journal-title":"Cancers (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100766","article-title":"Exploiting targeted nanomedicine for surveillance, diagnosis, and treatment of hepatocellular carcinoma","volume":"22","author":"Liu T","year":"2023","unstructured":"Liu T, Liu L, Li L, Cai J. Exploiting targeted nanomedicine for surveillance, diagnosis, and treatment of hepatocellular carcinoma. Mater Today Bio. 2023, 22:100766. 10.1016\/j.mtbio.2023.100766","journal-title":"Mater Today Bio"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/jcu.23197","article-title":"The clinical value of dual-energy computed tomography and diffusion-weighted imaging in the context of liver cancer: a narrative review","volume":"50","author":"Fan PL","year":"2022","unstructured":"Fan PL, Chu J, Wang Q, Wang C. The clinical value of dual-energy computed tomography and diffusion-weighted imaging in the context of liver cancer: a narrative review. J Clin Ultrasound. 2022, 50:862-8. 10.1002\/jcu.23197","journal-title":"J Clin Ultrasound"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.4c03078","article-title":"Ultrathin Gd-oxide nanosheet as ultrasensitive companion diagnostic tool for MR imaging and therapy of submillimeter microhepatocellular carcinoma","volume":"24","author":"Zhang C","year":"2024","unstructured":"Zhang C, Wang X, Xu J, et al.. Ultrathin Gd-oxide nanosheet as ultrasensitive companion diagnostic tool for MR imaging and therapy of submillimeter microhepatocellular carcinoma. Nano Lett. 2024, 24:11002-11. 10.1021\/acs.nanolett.4c03078","journal-title":"Nano Lett"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2022.12.015","article-title":"Radiomics: a radiological evidence-based artificial intelligence technique to facilitate personalized precision medicine in hepatocellular carcinoma","volume":"55","author":"Wei J","year":"2023","unstructured":"Wei J, Jiang H, Zhou Y, Tian J, Furtado FS, Catalano OA. Radiomics: a radiological evidence-based artificial intelligence technique to facilitate personalized precision medicine in hepatocellular carcinoma. Dig Liver Dis. 2023, 55:833-47. 10.1016\/j.dld.2022.12.015","journal-title":"Dig Liver Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910271","article-title":"Immunological markers, prognostic factors and challenges following curative treatments for hepatocellular carcinoma","volume":"22","author":"Lee SK","year":"2021","unstructured":"Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological markers, prognostic factors and challenges following curative treatments for hepatocellular carcinoma. Int J Mol Sci. 2021, 22:10271. 10.3390\/ijms221910271","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.717687","article-title":"Diagnostic value of delayed PET\/MR in liver metastasis in comparison with PET\/CT","volume":"11","author":"Zhou N","year":"2021","unstructured":"Zhou N, Meng X, Zhang Y, et al.. Diagnostic value of delayed PET\/MR in liver metastasis in comparison with PET\/CT. Front Oncol. 2021, 11:717687. 10.3389\/fonc.2021.717687","journal-title":"Front Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14141466","article-title":"Influence of covariates on 18F-FDG PET\/CT diagnostic accuracy for liver metastasis","volume":"14","author":"Habouzit V","year":"2024","unstructured":"Habouzit V, Flaus A, Phelip JM, Grange S, Le Roy B, Grange R, Pr\u00e9vot N. Influence of covariates on 18F-FDG PET\/CT diagnostic accuracy for liver metastasis. Diagnostics (Basel). 2024, 14:1466. 10.3390\/diagnostics14141466","journal-title":"Diagnostics (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74311-w","article-title":"MRI radiomics model differentiates small hepatic metastases and abscesses in periampullary cancer patients","volume":"14","author":"Park JH","year":"2024","unstructured":"Park JH, Cho ES, Yoon J, Rhee HJ, Park J, Choi JY, Chung YE. MRI radiomics model differentiates small hepatic metastases and abscesses in periampullary cancer patients. Sci Rep. 2024, 14:23541. 10.1038\/s41598-024-74311-w","journal-title":"Sci Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-024-04548-6","article-title":"PET\/MRI: pictorial review of hepatobiliary and pancreatic applications","volume":"50","author":"Awali M","year":"2025","unstructured":"Awali M, El Homsi M, Fraum TJ, et al.. PET\/MRI: pictorial review of hepatobiliary and pancreatic applications. Abdom Radiol (NY). 2025, 50:875-901. 10.1007\/s00261-024-04548-6","journal-title":"Abdom Radiol (NY)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06099-8","article-title":"A lesson in humility: the added values of PET-MRI over PET-CT in detecting malignant hepatic lesions","volume":"50","author":"Cohen D","year":"2023","unstructured":"Cohen D, Kesler M, Muchnik Kurash M, Even-Sapir E, Levine C. A lesson in humility: the added values of PET-MRI over PET-CT in detecting malignant hepatic lesions. Eur J Nucl Med Mol Imaging. 2023, 50:1423-33. 10.1007\/s00259-022-06099-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020382","article-title":"Adding MRI as a surveillance test for hepatocellular carcinoma in patients with liver cirrhosis can improve prognosis","volume":"11","author":"Yu SJ","year":"2023","unstructured":"Yu SJ, Yoo JJ, Lee DH, et al.. Adding MRI as a surveillance test for hepatocellular carcinoma in patients with liver cirrhosis can improve prognosis. Biomedicines. 2023, 11:382. 10.3390\/biomedicines11020382","journal-title":"Biomedicines"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.29404","article-title":"Deep learning-based approach for identifying and measuring focal liver lesions on contrast-enhanced MRI","volume":"61","author":"Dai H","year":"2025","unstructured":"Dai H, Xiao Y, Fu C, et al.. Deep learning-based approach for identifying and measuring focal liver lesions on contrast-enhanced MRI. J Magn Reson Imaging. 2025, 61:111-20. 10.1002\/jmri.29404","journal-title":"J Magn Reson Imaging"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9919507","article-title":"CT image segmentation method of liver tumor based on artificial intelligence enabled medical imaging","volume":"2021","author":"Liu L","year":"2020","unstructured":"Liu L, Wang L, Xu D, et al.. CT image segmentation method of liver tumor based on artificial intelligence enabled medical imaging. Math Probl Eng. 2020, 2021:9919507. 10.1155\/2021\/9919507","journal-title":"Math Probl Eng"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-01018-8","article-title":"Transforming the landscape of liver cancer detection and care","volume":"22","author":"Yip TC","year":"2025","unstructured":"Yip TC, Wong GL. Transforming the landscape of liver cancer detection and care. Nat Rev Gastroenterol Hepatol. 2025, 22:86-7. 10.1038\/s41575-024-01018-8","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105079","article-title":"Precision oncology in biliary tract cancer: the emerging role of liquid biopsy","volume":"10","author":"de Scordilli M","year":"2025","unstructured":"de Scordilli M, Bortolot M, Torresan S, et al.. Precision oncology in biliary tract cancer: the emerging role of liquid biopsy. ESMO Open. 2025, 10:105079. 10.1016\/j.esmoop.2025.105079","journal-title":"ESMO Open"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00257-8","article-title":"Liquid biopsies in cancer","volume":"6","author":"Yin H","year":"2025","unstructured":"Yin H, Zhang M, Zhang Y, Zhang X, Zhang X, Zhang B. Liquid biopsies in cancer. Mol Biomed. 2025, 6:18. 10.1186\/s43556-025-00257-8","journal-title":"Mol Biomed"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246025","article-title":"Circulating tumor DNA-a novel biomarker of tumor progression and its favorable detection techniques","volume":"14","author":"Wen X","year":"2022","unstructured":"Wen X, Pu H, Liu Q, Guo Z, Luo D. Circulating tumor DNA-a novel biomarker of tumor progression and its favorable detection techniques. Cancers (Basel). 2022, 14:6025. 10.3390\/cancers14246025","journal-title":"Cancers (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual J","year":"2022","unstructured":"Pascual J, Attard G, Bidard FC, et al.. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022, 33:750-68. 10.1016\/j.annonc.2022.05.520","journal-title":"Ann Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2021.1889371","article-title":"Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations","volume":"21","author":"Andersson D","year":"2021","unstructured":"Andersson D, Kristiansson H, Kubista M, St\u00e5hlberg A. Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations. Expert Rev Mol Diagn. 2021, 21:299-310. 10.1080\/14737159.2021.1889371","journal-title":"Expert Rev Mol Diagn"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.692322","article-title":"Application of data science in circulating tumor DNA detection: a promising avenue towards liquid biopsy","volume":"11","author":"Li M","year":"2021","unstructured":"Li M, Xie S, Lu C, Zhu L, Zhu L. Application of data science in circulating tumor DNA detection: a promising avenue towards liquid biopsy. Front Oncol. 2021, 11:692322. 10.3389\/fonc.2021.692322","journal-title":"Front Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28565","article-title":"Analytical validation of NeXT Personal\u00ae, an ultra-sensitive personalized circulating tumor DNA assay","volume":"15","author":"Northcott J","year":"2024","unstructured":"Northcott J, Bartha G, Harris J, et al.. Analytical validation of NeXT Personal\u00ae, an ultra-sensitive personalized circulating tumor DNA assay. Oncotarget. 2024, 15:200-18. 10.18632\/oncotarget.28565","journal-title":"Oncotarget"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00857-z","article-title":"Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology","volume":"39","author":"Deveson IW","year":"2021","unstructured":"Deveson IW, Gong B, Lai K, et al.. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nat Biotechnol. 2021, 39:1115-28. 10.1038\/s41587-021-00857-z","journal-title":"Nat Biotechnol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03296-8","article-title":"Circulating tumour DNA for a minimal residual disease assessment and recurrence risk in hepatocellular carcinoma: a systematic review and meta-analysis","volume":"134","author":"Buonopane IR","year":"2026","unstructured":"Buonopane IR, Saldanha EF, de Menezes JS, et al.. Circulating tumour DNA for a minimal residual disease assessment and recurrence risk in hepatocellular carcinoma: a systematic review and meta-analysis. Br J Cancer. 2026, 134:699-706. 10.1038\/s41416-025-03296-8","journal-title":"Br J Cancer"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.3565","article-title":"Circulating tumor derived cell-free DNA (ctDNA) to predict recurrence of metastatic colorectal cancer (mCRC) following curative intent surgery or radiation","volume":"39","author":"Chee B","year":"2021","unstructured":"Chee B, Ibrahim F, Esquivel M, et al.. Circulating tumor derived cell-free DNA (ctDNA) to predict recurrence of metastatic colorectal cancer (mCRC) following curative intent surgery or radiation. J Clin Oncol. 2021, 39:3565. 10.1200\/JCO.2021.39.15_suppl.3565","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1141833","article-title":"Liquid biopsy can cure early colorectal cancer recurrence - case Report","volume":"13","author":"Baraniskin A","year":"2023","unstructured":"Baraniskin A, Baba HA, Theegarten D, Mika T, Schroers R, Klein-Scory S. Liquid biopsy can cure early colorectal cancer recurrence - case Report. Front Oncol. 2023, 13:1141833. 10.3389\/fonc.2023.1141833","journal-title":"Front Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00443","article-title":"Detecting early recurrence with circulating tumor DNA in stage I-III biliary tract cancer after curative resection","volume":"9","author":"Yu J","year":"2025","unstructured":"Yu J, He AR, Ouf M, et al.. Detecting early recurrence with circulating tumor DNA in stage I-III biliary tract cancer after curative resection. JCO Precis Oncol. 2025, 9:e2400443. 10.1200\/PO-24-00443","journal-title":"JCO Precis Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13126-x","article-title":"Optimizing circulating tumour DNA use in the perioperative setting for intrahepatic cholangiocarcinoma: diagnosis, screening, minimal residual disease detection and treatment response monitoring","volume":"30","author":"Choi WJ","year":"2023","unstructured":"Choi WJ, Ivanics T, Gravely A, Gallinger S, Sapisochin G, O'Kane GM. Optimizing circulating tumour DNA use in the perioperative setting for intrahepatic cholangiocarcinoma: diagnosis, screening, minimal residual disease detection and treatment response monitoring. Ann Surg Oncol. 2023, 30:3849-63. 10.1245\/s10434-023-13126-x","journal-title":"Ann Surg Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-06700-4","article-title":"Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know","volume":"30","author":"Calandri M","year":"2020","unstructured":"Calandri M, Siravegna G, Yevich SM, et al.. Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know. Eur Radiol. 2020, 30:4496-503. 10.1007\/s00330-020-06700-4","journal-title":"Eur Radiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/466236-integrating-circulating-tumor-dna-ctdna-into-postoperative-surveillance-after-the-resection-of-intrahepatic-cholangiocarcinoma-a-proposed-hybrid-imaging-molecular-framework","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T13:22:07Z","timestamp":1771593727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/466236-integrating-circulating-tumor-dna-ctdna-into-postoperative-surveillance-after-the-resection-of-intrahepatic-cholangiocarcinoma-a-proposed-hybrid-imaging-molecular-framework"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.103966","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,20]]}}}